Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission

Nanomedicine ◽  
2015 ◽  
Vol 10 (6) ◽  
pp. 899-914 ◽  
Author(s):  
Daniel Sepúlveda-Crespo ◽  
Javier Sánchez-Rodríguez ◽  
María Jesús Serramía ◽  
Rafael Gómez ◽  
Francisco Javier De La Mata ◽  
...  
Keyword(s):  
Sexual Transmission ◽  
Triple Combination ◽  
Carbosilane Dendrimers ◽  
Hiv 1

Development of sulphated and naphthylsulphonated carbosilane dendrimers as topical microbicides to prevent HIV-1 sexual transmission

AIDS ◽  
2013 ◽  
Vol 27 (8) ◽  
pp. 1219-1229 ◽  
Author(s):  
Enrique Vacas Córdoba ◽  
Eduardo Arnaiz ◽  
Miguel Relloso ◽  
Carlos Sánchez-Torres ◽  
Federico García ◽  
...  
Keyword(s):  
Sexual Transmission ◽  
Carbosilane Dendrimers ◽  
Topical Microbicides ◽  
Hiv 1

Polyanionic Functionalized Carbosilane Dendrimers as Potential Microbicides to Prevent HIV-1 Sexual Transmission

2014 ◽  
Vol 30 (S1) ◽  
pp. A204-A204 ◽  
Author(s):  
Enrique Vacas-Córdoba ◽  
Francisco J. De la Mata ◽  
Rafael Gómez ◽  
Marjorie Pion ◽  
M Ángeles Muñoz-Fernández
Keyword(s):  
Sexual Transmission ◽  
Carbosilane Dendrimers ◽  
Hiv 1

scholarly journals Antiviral mechanism of polyanionic carbosilane dendrimers against HIV-1

2016 ◽  
pp. 1281 ◽  
Author(s):  
Mariangeles Angeles Munoz-Fernandez ◽  
Enrique Vacas-Córdoba ◽  
Marek Maly ◽  
Francisco Javier de la Mata ◽  
Rafael Gómez ◽  
...  
Keyword(s):  
Carbosilane Dendrimers ◽  
Antiviral Mechanism ◽  
Hiv 1

scholarly journals Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials

BMJ ◽  
2019 ◽  
pp. l4179 ◽  
Author(s):  
Qi Feng ◽  
Aoshuang Zhou ◽  
Huachun Zou ◽  
Suzanne Ingle ◽  
Margaret T May ◽  
...  
Keyword(s):  
Randomised Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Triple Combination ◽  
Antiretroviral Therapies ◽  
Treatment Naïve ◽  
Randomised Controlled ◽  
Hiv 1 ◽  
Cd4 T Cell Count ◽  
Better Than

AbstractObjectiveTo evaluate the effects of four drug (quadruple) versus three drug (triple) combination antiretroviral therapies in treatment naive people with HIV, and explore the implications of existing trials for clinical practice and research.DesignSystematic review and meta-analysis of randomised controlled trials.Data sourcesPubMed, EMBASE, CENTRAL, Web of Science, and the Cumulative Index to Nursing and Allied Health Literature from March 2001 to December 2016 (updated search in PubMed and EMBASE up to June 2018); and reference lists of eligible studies and related reviews.Study selectionRandomised controlled trials comparing quadruple with triple combination antiretroviral therapies in treatment naive people with HIV and evaluating at least one effectiveness or safety outcome.Review methodsOutcomes of interest included undetectable HIV-1 RNA, CD4 T cell count, virological failure, new AIDS defining events, death, and severe adverse effects. Random effects meta-analyses were conducted.ResultsTwelve trials (including 4251 people with HIV) were eligible. Quadruple and triple combination antiretroviral therapies had similar effects on all relevant effectiveness and safety outcomes, with no point estimates favouring quadruple therapy. With the triple therapy as the reference group, the risk ratio was 0.99 (95% confidence interval 0.93 to 1.05) for undetectable HIV-1 RNA, 1.00 (0.90 to 1.11) for virological failure, 1.17 (0.84 to 1.63) for new AIDS defining events, 1.23 (0.74 to 2.05) for death, and 1.09 (0.89 to 1.33) for severe adverse effects. The mean difference in CD4 T cell count increase between the two groups was −19.55 cells/μL (−43.02 to 3.92). In general, the results were similar, regardless of the specific regimens of combination antiretroviral therapies, and were robust in all subgroup and sensitivity analyses.ConclusionIn this study, effects of quadruple combination antiretroviral therapy were not better than triple combination antiretroviral therapy in treatment naive people with HIV. This finding lends support to current guidelines recommending the triple regimen as first line treatment. Further trials on this topic should be conducted only when new research is justified by adequate systematic reviews of the existing evidence. However, this study cannot exclude the possibility that quadruple cART would be better than triple cART when new classes of antiretroviral drugs are made available.

scholarly journals ADS-J1 Inhibits Semen-Derived Amyloid Fibril Formation and Blocks Fibril-Mediated Enhancement of HIV-1 Infection

2015 ◽  
Vol 59 (9) ◽  
pp. 5123-5134 ◽  
Author(s):  
Tianrong Xun ◽  
Wenjuan Li ◽  
Jinquan Chen ◽  
Fei Yu ◽  
Wei Xu ◽  
...  
Keyword(s):  
Viral Infection ◽  
Amyloid Fibrils ◽  
Synergistic Effects ◽  
Sexual Transmission ◽  
Prostatic Acid Phosphatase ◽  
Fibril Formation ◽  
Antiretroviral Drugs ◽  
Target Cells ◽  
Additional Function ◽  
Hiv 1

ABSTRACTSemen-derived enhancer of viral infection (SEVI) is composed of amyloid fibrils that can greatly enhance HIV-1 infectivity. By its cationic property, SEVI promotes viral sexual transmission by facilitating the attachment and internalization of HIV-1 to target cells. Therefore, semen-derived amyloid fibrils are potential targets for microbicide design. ADS-J1 is an anionic HIV-1 entry inhibitor. In this study, we explored an additional function of ADS-J1: inhibition of SEVI fibril formation and blockage of SEVI-mediated enhancement of viral infection. We found that ADS-J1 bound to an amyloidogenic peptide fragment (PAP248–286, comprising amino acids 248 to 286 of the enzyme prostatic acid phosphatase), thereby inhibiting peptide assembly into amyloid fibrils. In addition, ADS-J1 binds to mature amyloid fibrils and antagonizes fibril-mediated enhancement of viral infection. Unlike cellulose sulfate, a polyanion that failed in clinical trial to prevent HIV-1 sexual transmission, ADS-J1 shows no ability to facilitate fibril formation. More importantly, the combination of ADS-J1 with several antiretroviral drugs exhibited synergistic effects against HIV-1 infection in semen, with little cytotoxicity to vaginal epithelial cells. Our results suggest that ADS-J1 or a derivative may be incorporated into a combination microbicide for prevention of the sexual transmission of HIV-1.

No evidence for proliferation in the blood CD4+ T-cell pool during HIV-1 infection and triple combination therapy

AIDS ◽  
1998 ◽  
Vol 12 (8) ◽  
pp. 879-884 ◽  
Author(s):  
Olivier Tissot ◽  
Jean-Paul Viard ◽  
Cécile Rabian ◽  
Nicole Ngo ◽  
Marianne Burgard ◽  
...  
Keyword(s):  
T Cell ◽  
Combination Therapy ◽  
Cd4 T Cell ◽  
Triple Combination ◽  
Triple Combination Therapy ◽  
Cell Pool ◽  
Hiv 1

Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania

The Lancet ◽  
2000 ◽  
Vol 356 (9224) ◽  
pp. 113-121 ◽  
Author(s):  
Michael Sweat ◽  
Steven Gregorich ◽  
Gloria Sangiwa ◽  
Colin Furlonge ◽  
Donald Balmer ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Sexual Transmission ◽  
Sexual Transmission Of Hiv ◽  
Hiv 1

scholarly journals Engineering of Lactobacillus jensenii To Secrete RANTES and a CCR5 Antagonist Analogue as Live HIV-1 Blockers

2010 ◽  
Vol 54 (7) ◽  
pp. 2994-3001 ◽  
Author(s):  
Luca Vangelista ◽  
Massimiliano Secchi ◽  
Xiaowen Liu ◽  
Angela Bachi ◽  
Letong Jia ◽  
...  
Keyword(s):  
T Cells ◽  
Sexual Transmission ◽  
Ccr5 Antagonist ◽  
Strong Activity ◽  
Promising Strategy ◽  
Lactobacillus Jensenii ◽  
Proinflammatory Activity ◽  
Anti Hiv ◽  
Hiv 1 ◽  
Prevention Of Hiv

ABSTRACT The development of effective microbicides for the prevention of HIV-1 sexual transmission represents a primary goal for the control of AIDS epidemics worldwide. A promising strategy is the use of bacteria belonging to the vaginal microbiota as live microbicides for the topical production of HIV-1 inhibitors. We have engineered a human vaginal isolate of Lactobacillus jensenii to secrete the anti-HIV-1 chemokine RANTES, as well as C1C5 RANTES, a mutated analogue that acts as a CCR5 antagonist and therefore is devoid of proinflammatory activity. Full-length wild-type RANTES and C1C5 RANTES secreted by L. jensenii were purified to homogeneity and shown to adopt a correctly folded conformation. Both RANTES variants were shown to inhibit HIV-1 infection in CD4+ T cells and macrophages, displaying strong activity against HIV-1 isolates of different genetic subtypes. This work provides proof of principle for the use of L. jensenii-produced C1C5 RANTES to block HIV-1 infection of CD4+ T cells and macrophages, setting the basis for the development of a live anti-HIV-1 microbicide targeting CCR5 in an antagonistic manner.

scholarly journals Number of HIV-1 founder variants is determined by the recency of the source partner infection

Science ◽  
2020 ◽  
Vol 369 (6499) ◽  
pp. 103-108 ◽  
Author(s):  
Ch. Julián Villabona-Arenas ◽  
Matthew Hall ◽  
Katrina A. Lythgoe ◽  
Stephen G. Gaffney ◽  
Roland R. Regoes ◽  
...  
Keyword(s):  
Early Stage ◽  
Control Strategies ◽  
Sexual Transmission ◽  
Low Frequency ◽  
Epidemiological Data ◽  
High Genetic Diversity ◽  
Partner Characteristics ◽  
Infection Stage ◽  
Hiv 1 ◽  
Founder Strain

During sexual transmission, the high genetic diversity of HIV-1 within an individual is frequently reduced to one founder variant that initiates infection. Understanding the drivers of this bottleneck is crucial to developing effective infection control strategies. Little is known about the importance of the source partner during this bottleneck. To test the hypothesis that the source partner affects the number of HIV founder variants, we developed a phylodynamic model calibrated using genetic and epidemiological data on all existing transmission pairs for whom the direction of transmission and the infection stage of the source partner are known. Our results suggest that acquiring infection from someone in the acute (early) stage of infection increases the risk of multiple–founder variant transmission compared with acquiring infection from someone in the chronic (later) stage of infection. This study provides the first direct test of source partner characteristics to explain the low frequency of multiple–founder strain infections.

scholarly journals Enhancement of Human Immunodeficiency Virus Type 1 Replication Is Not Intrinsic to All Polyanion-Based Microbicides

2009 ◽  
Vol 53 (8) ◽  
pp. 3565-3568 ◽  
Author(s):  
Secondo Sonza ◽  
Adam Johnson ◽  
David Tyssen ◽  
Tim Spelman ◽  
Gareth R. Lewis ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Mononuclear Cells ◽  
Human Peripheral Blood ◽  
Sexual Transmission ◽  
Intrinsic Property ◽  
Enhancement Effect ◽  
Peripheral Blood Mononuclear ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACT Polyanion-based microbicides have been developed to prevent the sexual transmission of human immunodeficiency virus (HIV). Recent data suggest that polyanions have the capacity to enhance HIV type 1 (HIV-1) replication at threshold antiviral concentrations. Evaluation of the microbicide candidates SPL7013 and PRO 2000 revealed no specific enhancement of two CCR5 HIV-1 strains in human peripheral blood mononuclear cells compared to enfuvirtide (Fuzeon). The enhancement effect is likely to be a function of the assay conditions and is not an intrinsic property of these polyanions.

Sign in / Sign up

Export Citation Format

Share Document